Cancer medicine · 2025
PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yanru, Cao Junjie, Huang Rong, Lou Junyi, Gu Junxian, Luo Zining, Yao Tianliang, Xie Jiebin
Аннотация
BACKGROUND: Prostate cancer remains one of the most prevalent cancers among men worldwide, particularly in the context of metastatic castration-resistant prostate cancer (mCRPC), which poses significant treatment challenges. PARP inhibitors offer a promising therapeutic option for patients with homologous recombination repair (HRR) deficiencies.
METHODS: This study systematically analyzed 630 registered clinical trials related to prostate cancer and PARP inhibitors as of April 25, 2025. A total of 109 trials were included, focusing on key information such as year of initiation, trial phase, targeted populations, and study designs.
RESULTS: Our findings indicate a significant increase in clinical trials involving PARP inhibitors from 2012 to 2025. Multi-national collaborative studies accounted for 39.4% of the trials, with the United States being the principal contributing country. The majority of trials are concentrated on targeting PARP1 and PARP2 at various phases of development.
CONCLUSIONS: PARP inhibitors have demonstrated breakthrough advancements in the treatment of mCRPC; however, challenges such as resistance and the need for personalized therapies persist. Future research should emphasize target identification and the exploration of combination therapy strategies to enhance clinical efficacy.
METHODS: This study systematically analyzed 630 registered clinical trials related to prostate cancer and PARP inhibitors as of April 25, 2025. A total of 109 trials were included, focusing on key information such as year of initiation, trial phase, targeted populations, and study designs.
RESULTS: Our findings indicate a significant increase in clinical trials involving PARP inhibitors from 2012 to 2025. Multi-national collaborative studies accounted for 39.4% of the trials, with the United States being the principal contributing country. The majority of trials are concentrated on targeting PARP1 and PARP2 at various phases of development.
CONCLUSIONS: PARP inhibitors have demonstrated breakthrough advancements in the treatment of mCRPC; however, challenges such as resistance and the need for personalized therapies persist. Future research should emphasize target identification and the exploration of combination therapy strategies to enhance clinical efficacy.